Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

NCT04588194 is registered in ClinicalTrials.gov with David Gomez Almaguer as lead sponsor.

NCT NCT04588194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Lead sponsor
David Gomez Almaguer
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2020
Completion date
November 1, 2022
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia, thrombotic thrombocytopenic purpura